# ScoreItem: Ecodopplercardiograma - LAVI

**ID:** `c77cedd3-2800-7118-a779-d328ee6e2831`
**FullName:** Ecodopplercardiograma - LAVI (Exames - Imagem)
**Unit:** mL/m¬≤

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 20 artigos
- Avg Similarity: 0.558

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7118-a779-d328ee6e2831`.**

```json
{
  "score_item_id": "c77cedd3-2800-7118-a779-d328ee6e2831",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Ecodopplercardiograma - LAVI (Exames - Imagem)
**Unidade:** mL/m¬≤

**30 chunks de 20 artigos (avg similarity: 0.558)**

### Chunk 1/30
**Article:** Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update From the American Society of Echocardiography (2025)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.684

Updated guidelines for the evaluation of left ventricular diastolic function incorporating LAVI as a key parameter in the assessment algorithm. LAVI is an integral part of routine evaluation of patients with dyspnea or heart failure, providing powerful predictive marker of LV diastolic dysfunction.

---

### Chunk 2/30
**Article:** Prognostic Significance of Left Atrial Volume Index in Acute Coronary Syndrome (2024)
**Journal:** Journal of the Practice of Cardiovascular Sciences
**Section:** abstract | **Similarity:** 0.637

Study demonstrating that LAVI acts as a powerful prognostic marker of adverse events and mortality in patients with acute coronary syndrome. Patients with increased LAVI have significantly worse long-term prognosis. Severe LA enlargement (LAVI >48 mL/m¬≤) was an independent predictor of all-cause mortality (HR: 11.153; 95% CI: 1.924-64.642, p=0.007).

---

### Chunk 3/30
**Article:** Left Atrial Volume Index by Echocardiography: Improved, Objective, and Simplified Cutoff Values for Abnormality Based on Association With Survival (2024)
**Journal:** Heart, Lung and Circulation
**Section:** abstract | **Similarity:** 0.620

Comprehensive study establishing simplified cutoff values for LAVI abnormality based on survival outcomes. Normal LAVI ‚â§34 mL/m¬≤, mildly abnormal 35-41 mL/m¬≤, moderately abnormal 42-48 mL/m¬≤, severely abnormal >48 mL/m¬≤. Stepwise increase in mortality risk with each increment of LAVI class. Severe LAVI associated with 42% increased mortality risk.

---

### Chunk 4/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.582

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16‚Äì22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindb√§ck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649‚Äì652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438‚Äì439.[CrossRef]
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;R√ºckerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 5/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.573

il√¢ncia aumentada nas mulheres.**
- Pr√©-menopausa: incid√™ncia de eventos cardiovasculares em mulheres √© muito menor (raz√µes 1:20 a 1:30 versus homens).
- P√≥s-menopausa: aproxima√ß√£o para quase 1:1, refletindo a perda do efeito protetor do estrog√™nio e a mudan√ßa no perfil de risco.
**Additional Key Findings**
- Limiares de exposi√ß√£o/oxida√ß√£o do LDL: acima de 0,8 h√° maior exposi√ß√£o do LDL √† oxida√ß√£o; alvo desej√°vel ‚â§0,7‚Äì0,8.
- Evid√™ncia hist√≥rica (Interarte, 2004) e revis√µes recentes (2023) sustentam a evolu√ß√£o do conhecimento sobre D, resist√™ncia √† insulina e risco cardiovascular.
- Lp(a) tem ~90% de variabilidade gen√©tica, indicando forte determina√ß√£o heredit√°ria e necessidade de estrat√©gias espec√≠ficas.
- Semaglutida em IC diast√≥lica e obesidade: estudo com n=529 mostrou redu√ß√£o de peso de 10% e apenas 1 evento de morte por IC no grupo tratado, sugerindo benef√≠cio cl√≠nico.

---

### Chunk 6/30
**Article:** Left atrial volume assessed by echocardiography identifies patients with high risk of adverse outcome after acute myocardial infarction (2024)
**Journal:** Echo Research & Practice
**Section:** abstract | **Similarity:** 0.568

Study demonstrating compelling association between augmented LA volume and subsequent all-cause mortality over median follow-up of 3.8 years. Reaffirms importance of LA volume as critical parameter for evaluating cardiovascular risk and determining patient prognosis following AMI, even with contemporary treatment.

---

### Chunk 7/30
**Article:** Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography (2015)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.566

Updated guidelines for echocardiographic assessment. Normal LVEF ‚â•54% in women by Simpson method. Sex-specific reference ranges are essential for accurate diagnosis of systolic dysfunction.

---

### Chunk 8/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.562

N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmitralowvelocity;E‚Ä≤,earlydiastolicmitralannularvelocity;TAPSE,tricuspidannularplaneexcursion;PASP,pulmonaryarterialsystolicpressure;RVOT-AT,rightventricularoutowtractaccelerationtime;VO2peak,peakoxygenconsumption;NYHA,NewYorkHeartAssociation;AF,atrialbrillation;ACE-I,angiotensin-converting-enzymeinhibitors;ARBs,angiotensin-receptorblockers;MRA,mineralocorticoid-receptorantagonist;ICD,implantablecardioverter-debrillator;CRT,cardiacresynchronizationtherapy;IGF-1D,IGF-1deciency;DHEA-SD,DHEA-Sdeciency.

---

### Chunk 9/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.560

calPracticeGuidelines.JAmCollCardiol2022;79:1757‚Äì1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-L√≥pezE,BarallatJ,Cserk√≥ov√°A,G√°lvez-Mont√≥nC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsiderationsinbiomarkerresearch:Focusoncardiovasculardisease.ClinChemLabMed.2021;59:1747‚Äì1760.5.Pop-BusuiR,JanuzziJL,BruemmerD,ButaliaS,GreenJB,HortonWB,etal.Heartfailure:Anunderappreciatedcomplicationofdiabetes.Aconsensusreportofthe
AmericanDiabetesAssociation.DiabetesCare2022;45:1670‚Äì1690.https://doi.org/10.2337/dci22-00146.BozkurtB,CoatsAJS,TsutsuiH,AbdelhamidCM,AdamopoulosS,AlbertN,etal.Universaldenitionandclassicationofheartfailure:AreportoftheHeartFailureSocietyofAmerica,HeartFailureAssociationoftheEuropean
SocietyofCardiology,JapaneseHeartFailureSocietyandWritingCommittee
oftheUniversalDenitionofHeartFailure:EndorsedbytheCanadianHeart
FailureSociety,HeartFailureAssociationofIndia,CardiacSocietyofAustralia
andNewZealand,andChineseHeartFailureAssociation.EurJHeartFail2021;23:352‚Äì

---

### Chunk 10/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.559

herauthorshavenothing
todisclose.References1.McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,B√∂hmM,etal.;ESCScienticDocumentGroup.2021ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure:DevelopedbytheTaskForcefor
thediagnosisandtreatmentofacuteandchronicheartfailureoftheEuropean
SocietyofCardiology(ESC).WiththespecialcontributionoftheHeartFailure
Association(HFA)oftheESC.EurJHeartFail2022;24:4‚Äì131.https://doi.org/10.1002/ejhf.23332.Guidelinesforthediagnosisofheartfailure.TheTaskForceonHeartFailureoftheEuropeanSocietyofCardiology.EurHeartJ1995;16:741‚Äì751.3.HeidenreichPA,BozkurtB,AguilarD,AllenLA,ByunJJ,ColvinMM,etal.AHA/ACC/HFSAGuidelineforthemanagementofheartfailure:Executive
summary:AreportoftheAmericanCollegeofCardiology/AmericanHeart
AssociationJointCommitteeonClinicalPracticeGuidelines.JAmCollCardiol2022;79:1757‚Äì1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-L√≥pezE,BarallatJ,Cserk√≥ov√°A,G√°lvez-Mont√≥nC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsid

---

### Chunk 11/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.557

co da dislipidemia.
- [ ] 2. Analisar criticamente os estudos sobre o Inclisiran (Cibrava), focando na diferen√ßa entre desfechos substitutos (redu√ß√£o de LDL) e desfechos cl√≠nicos duros (mortalidade, infarto, AVC).
- [ ] 3. Utilizar o site `the-nnt.com` para pesquisar o NNT e NNH de outros medicamentos prescritos na pr√°tica cl√≠nica.
- [ ] 4. Refletir sobre a influ√™ncia da ind√∫stria farmac√™utica e dos interesses financeiros na prescri√ß√£o de novos medicamentos.
- [ ] 5. Estudar a diferen√ßa entre risco relativo e risco absoluto para interpretar criticamente os achados de estudos cient√≠ficos.
- [ ] 6. Pesquisar sobre os diferentes tipos de √¥mega-3 (EPA, DHA, ALA) e suas formula√ß√µes para entender como a qualidade do suplemento afeta os resultados.
- [ ] 7. Investigar os exames de subfracionamento de LDL e a rela√ß√£o ApoA/ApoB como ferramentas de avalia√ß√£o de risco cardiovascular mais precisas que o LDL total.
- [ ] 8.

---

### Chunk 12/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.556

¬±SDMean¬±SDMean¬±SDAge(years)66.18¬±10.2668.93¬±9.74564.89¬±10.3250.12NTproBNP(pg/ml)2597.05¬±4093.042794.47¬±3380.142504.52¬±4409.550.72
BSA(m2)1.70¬±0.161.68¬±0.11.71¬±0.190.34SBP(mmHg)123.29¬±17.82121.32¬±16.86124.24¬±18.370.53DBP(mmHg)75.46¬±12.3975.05¬±9.5175.65¬±13.650.85
eGFR(ml/min)68.61¬±34.2854.27¬±23.0275.55¬±36.760.001
Haemoglobin(g/dl)12.85¬±1.5312.50¬±1.2113.01¬±1.650.13Albumin(%)56.8¬±5.256.6¬±7.756.9¬±3.70.9Testosterone(ng/dl)48.80¬±61.8613.60¬±6.6362.55¬±68.16<0.001Ejectionfraction(%)33.81¬±6.4633.20¬±7.6634.10¬±5.850.53
LAVi(ml/m2)49.46¬±25.5755.51¬±30.2446.63¬±22.770.17e/E‚Ä≤14.68¬±9.9613.04¬±4.9512.53¬±6.400.16TAPSE(mm)18.82¬±4.5117.78¬±4.2619.31¬±4.560.12
PASP(mmHg)34.38¬±13.2537.69¬±13.7232.84¬±12.840.98
RVOT-AT(ms)103.27¬±36.47112.11¬±34.7497.15¬±37.730.35TAPSE/PASP(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31

---

### Chunk 13/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.554

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 14/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.549

rmed
instudiesinvolvinghumanparticipantswereinaccordancewiththeethicalstandardsoftheinstitutionaland/orna-tionalresearchcommitteeandwiththe1964Declaration
ofHelsinkianditslateramendmentsorcomparableethicalstandards.Medicalhistory,medicationuse,andclinicaldatawerere-cordedatthetimeoftheenrolmentasalreadydescribed.6,11Briey,patientsunderwentechocardiography(includingtwo-dimensional,Doppler,Color,andtissueDoppleranalysis)and
symptom-limitedexercisetestandmaximaloxygenuptake(VO2max)wasmeasuredbyabreath-to-breathrespiratorygasanalysis.Bloodsampleswerecollectedbyvenipuncture
afterovernightfast.Toobtainserumandplasma,sampleswerecentrifugedwithin30min,frozen,andstoredat80¬∞Cuntilassayed.SerumN-terminalprohormonebrainnatriureticpeptide(NT-proBNP)concentrationsweremea-suredbyanelectrochemiluminescenceimmunoassay(ECLIAbyRochediagnostics)usingaRocheElecsysanalyser.Serumhormoneswereanalysedinacentralizedcore-lab(IRCCSSDN,Naples,Italy).Insulinandinsulingrowth
2A.M.Marraetal.ESCHeartFailure(2022)DO

---

### Chunk 15/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.548

o de Diagn√≥stico:
1.  **Hist√≥rico M√©dico:** O conte√∫do √© uma palestra m√©dica sobre fatores de risco cardiovascular contempor√¢neos, n√£o uma consulta com um paciente espec√≠fico.
2.  **Hist√≥rico de Medica√ß√£o:** Inserir mais aqui
## Subjetivo:
O conte√∫do √© uma palestra m√©dica e n√£o cont√©m queixas subjetivas de um paciente.
## Objetivo:
O conte√∫do √© uma palestra m√©dica e n√£o cont√©m achados de exames de um paciente espec√≠fico. O palestrante menciona seus pr√≥prios resultados de exames como exemplo:
-   **√çndice de √îmega-3:** 6.7 (ideal entre 3 e 14).
-   **Rela√ß√£o √îmega-6 para √îmega-3:** 5:1 (ideal de 2:1 a 3:1), apesar da suplementa√ß√£o.
## Diagn√≥stico Prim√°rio:
-   **Avalia√ß√£o:** O texto √© uma apresenta√ß√£o educacional sobre fatores de risco inflamat√≥rios e metab√≥licos para doen√ßas vasculares, que s√£o frequentemente negligenciados na cardiologia tradicional. Os principais fatores discutidos incluem:
    -   Desequil√≠brio entre √îmega-3 e √îmega-6.

---

### Chunk 16/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.547

diseasedurationandlowdensitylipoproteincholesterollevels.JAmCollCardiol
1996:28:573‚Äì579.50Pedersen&Saltin
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

CoakleyEH,RimmEB,ColditzG,KawachiI,WillettW.Predictorsofweightchangeinmen:resultsfrom
theHealthProfessionalsFollow-upStudy.IntJObesRelatMetabDisord1998:22:89‚Äì96.CoatsAJ,AdamopoulosS,MeyerTE,ConwayJ,SleightP.Effectsofphysicaltraininginchronicheartfailure.Lancet1990:335:63‚Äì66.CoatsAJ,AdamopoulosS,RadaelliA,McCanceA,MeyerTE,BernardiL,SoldaPL,DaveyP,OrmerodO,ForfarC.Controlledtrialofphysical
traininginchronicheartfailure.

---

### Chunk 17/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.546

(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31%)0.98III23(24.46%)7(23.33%)16(25.00%)0.87
IV5(5.33%)2(6.67%)3(4.69%)0.65Aetiology(ischaemic)27(28.7%)17(56.7%)10(15.6%)0.01Yearofdisease5[2‚Äì10.75]4[1‚Äì9.75]7[2.75‚Äì12]0.1AF11(22.4%)4(13.33%)7(10.90%)0.73
Beta-blockers66(91.7%)24(72.00%)42(65.60%)0.15
ACE-I31(43.1%)12(40.00%)19(29.70%)0.22ARBs26(36.1%)9(30.00%)17(26.60%)0.72MRA26(36.1%)8(26.70%)18(28.12%)0.88
ICD26(36.6%)8(26.66%)18(28.10%)0.88
CRT10(14.1%)1(3.33%)9(14.10%)0.15IGF-1D50(53.2%)16(53.3%)34(53.1%)0.98DHEA-SD73(77.7%)29(97.7%)44(68.7%)0.01
TypeIIdiabetes26(27.7%)6(20%)20(31.2)0.37Abbreviations:TD,testosteronedeciency;NTproBNP,N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmit

---

### Chunk 18/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.544

alDenitionofHeartFailure:EndorsedbytheCanadianHeart
FailureSociety,HeartFailureAssociationofIndia,CardiacSocietyofAustralia
andNewZealand,andChineseHeartFailureAssociation.EurJHeartFail2021;23:352‚Äì380.https://doi.org/10.1002/ejhf.21157.ChioncelO,LainscakM,SeferovicPM,AnkerSD,Crespo-LeiroMG,HarjolaVP,etal.Epidemiologyandone-yearoutcomesinpatientswithchronicheartfailureandpreserved,mid-rangeandreducedejectionfraction:AnanalysisoftheESCHeartFailureLong-TermRegistry.EurJHeartFail2017;19:1574‚Äì1585.https://doi.org/10.1002/ejhf.8138.MukoyamaM,NakaoK,HosodaK,SugaS,SaitoY,OgawaY,etal.Brainnatriureticpeptideasanovelcardiachormoneinhumans.Evidenceforan
exquisitedualnatriureticpeptidesystem,atrialnatriureticpeptideandbrain
natriureticpeptide.JClinInvest1991;87:1402‚Äì1412.https://doi.org/10.1172/JCI1151469.PembertonCJ,JohnsonML,YandleTG,EspinerEA.Deconvolutionanalysisofcardiacnatriureticpeptidesduringacutevolumeoverload.Hypertension2000;36:355‚Äì359.https://doi.org/10.1161/01.hyp.36.3.35510.M

---

### Chunk 19/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.542

, apoiando a personaliza√ß√£o baseada em perfis de risco cumulativos, n√£o em um √∫nico marcador.
**Achados Adicionais**
- O cardi√¥metro de mortalidade cardiovascular iniciou monitoramento em 11/6/2024, contextualizando a urg√™ncia de interven√ß√µes cont√≠nuas.
- Diretrizes de tratamento costumam usar um limiar de 7,5% de risco para estatinas, mas exemplos pr√°ticos ilustram faixas de 2‚Äì4% em que a decis√£o deve considerar CAC e ApoB.
- Quase 40% dos indiv√≠duos com LDL muito elevado podem n√£o apresentar aterosclerose, refor√ßando heterogeneidade do risco.
- Colesterol total de 300 frequentemente acompanha LDL >190, mas a decis√£o terap√™utica deve ser guiada por risco global.
- Revis√µes de 2019 na Annals of Internal Medicine sobre carne vermelha/processada fornecem contexto adicional para dietas cardiometab√≥licas.
- Editorial de 2020 sobre hipercolesterolemia familiar difundiu o conceito ‚ÄúPower of Zero‚Äù, ampliando o uso do CAC na estratifica√ß√£o.

---

### Chunk 20/30
**Article:** Predictive value of electrocardiographic left ventricular hypertrophy in the general population: A meta-analysis (2020)
**Journal:** Journal of Electrocardiology
**Section:** abstract | **Similarity:** 0.539

This meta-analysis examined electrocardiographic left ventricular hypertrophy (LVH) as a predictor of adverse cardiac outcomes in 58,400 participants across 10 studies. The Sokolow-Lyon voltage, Cornell voltage, and Cornell product criteria showed comparable ability in predicting major adverse cardiovascular events (MACE), with risk ratios ranging from 1.56 to 1.70. The pooled risk ratio of MACE was 1.62 (95% CI 1.40-1.89) for Sokolow-Lyon voltage criteria. The pooled risk ratio of all-cause mortality was 1.47 (95% CI 1.10-1.97), and cardiovascular mortality was 1.38 (95% CI 1.19-1.60) for Sokolow-Lyon criteria. Cornell voltage demonstrated stronger predictive value for cardiovascular and all-cause mortality outcomes.

---

### Chunk 21/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.539

vida e identificar fatores de risco para inflama√ß√£o e disfun√ß√£o endotelial (dieta, estresse, sedentarismo).
- [ ] 2. Utilizar a calculadora MESA Risk para determinar o risco cardiovascular dos pacientes e considerar a solicita√ß√£o do Escore de C√°lcio Coronariano antes de prescrever estatinas em preven√ß√£o prim√°ria.
- [ ] 3. Ao avaliar o risco cardiovascular, solicitar exames avan√ßados como a rela√ß√£o ApoB/ApoA, subpart√≠culas de lipoprote√≠nas e anti-LDL oxidado para uma an√°lise mais aprofundada.
- [ ] 4. Em pacientes de preven√ß√£o prim√°ria, mesmo com colesterol alto, priorizar mudan√ßas no estilo de vida antes de considerar o uso de estatinas.
- [ ] 5. Reservar o uso de estatinas principalmente para pacientes em preven√ß√£o secund√°ria ou de alt√≠ssimo risco, focando nos seus efeitos pleotr√≥picos.
- [ ] 6.

---

### Chunk 22/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.538

m DCV), condi√ß√µes gestacionais (pr√©-termo, hipertensivas, diabetes gestacional), autoimunidade, tratamento de c√¢ncer de mama e defici√™ncias hormonais (climat√©rio/menopausa), frequentemente subvalorizadas nos protocolos. O palestrante defende abordagem multidisciplinar e estruturada de estilo de vida, especialmente em hipertens√£o lim√≠trofe, apoiada por nutricionistas e educa√ß√£o para ades√£o.
O uso de estatinas √© discutido criticamente: reconhece-se benef√≠cio anti-inflamat√≥rio local no p√≥s-angioplastia (les√£o de parede e fragilidade do stent), por√©m questiona-se o uso indiscriminado, sobretudo em preven√ß√£o prim√°ria, citando meta-an√°lise que desafia a hip√≥tese lip√≠dica e alertando para vieses na interpreta√ß√£o de risco relativo vs. absoluto. Em UTI, menciona-se aumento de del√≠rio e a necessidade de evitar ‚Äúreceita de bolo‚Äù (anticoagula√ß√£o, IBP, estatina autom√°tica).

---

### Chunk 23/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.537

s.%in
prior).Bycontrast,whencomparingtheproportionof
LOEBandCrecommendationsinpriorACC/AHAguidelines
andcurrentguidelines,theproportionofLOEBrecommen-
dationsincreased(median,.%vs	.%)andthepropor-
tionofLOECrecommendationsdecreased(median,	.%
vs
.%).WhenlookingatnumberratherthanproportionofLOEArecommendations,findingsweresimilar:Themediannum-
berofLOEArecommendationsinpriorguidelineswas
.	(	th-	thpercentiles,.	-.)comparedwith.	LevelsofEvidenceSupportingACC/AHAandESCGuidelines,2008-2018OriginalInvestigationResearchjama.com(Reprinted)JAMAMarch19,2019Volume321,Number111071¬©2019AmericanMedicalAssociation.Allrightsreserved.
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

(	th-	thpercentiles,
.

---

### Chunk 24/30
**Article:** Urea levels and cardiovascular disease in patients with chronic kidney disease (2022)
**Journal:** Nephrology Dialysis Transplantation
**Section:** other | **Similarity:** 0.537

sity,VersaillesSaintQuentinUniversity,INSERMUMRS,1018Villejuif,France,5DepartmentofCardiology,AmbroisePar√©UniversityHospital,APHP,Boulogne-Billancourt,Paris,France,6BiomedecineAgency,SaintDenisLaPlaine,France,7Universit√©deLyon,CarMeNINSERM,Lyon,France,8NephrologyDepartment,CHRUdeNancy,Vandoeuvre-l√®s-Nancy,France,9LorraineUniversity,APEMAC,Vandoeuvre-l√®s-Nancy,France,10NephrologyDepartment,CentreHospitalierLyonSud,Pierre-B√©nite,France,11ServicedeN√©phrologieTransplantationDialyseAph√©r√®se,CentreHospitalierUniversitairedeBordeaux,Bordeaux,France,12INSERM,U1026,UnivBordeauxSegalen,Bordeaux,Franceand13ArborResearchCollaborativeforHealth,AnnArborMI,USA‚àóTheseauthorscontributedequallytothiswork.Correspondenceto:ZiadA.Massy;E-mail:ziad.massy@aphp.fr;SophieLiabeuf;E-mail:liabeuf.sophie@chu-amiens.frGRAPHICALABSTRACT
¬©TheAuthor(s)2022.PublishedbyOxfordUniversityPressonbehalfoftheERA.ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttribution-NonCommercialLicense(htt

---

### Chunk 25/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.536

meta-analysis.LancetDiabetesEndocrinol20164(10):840‚Äì849.https://doi.org/10.1016/S2213-8587(16)30196-649.SciricaBM,BraunwaldE,RazI,CavenderMA,MorrowDA,JarolimP,etal.SAVOR-TIMI53SteeringCommitteeandInvestigators*.Heartfail-ure,saxagliptin,anddiabetesmellitus:ObservationsfromtheSAVOR-TIMI
53randomizedtrial.Circulation2014;130:1579‚Äì1588.https://doi.org/10.1161/CIRCULATIONAHA.114.010389...............50.MagnussonM,MelanderO,IsraelssonB,GrubbA,GroopL,JovingeS.ElevatedplasmalevelsofNt-proBNPinpatientswithtype2diabeteswithoutovert
cardiovasculardisease.DiabetesCare2004;27:1929‚Äì1935.https://doi.org/10.2337/diacare.27.8.192951.VermaS,SharmaA,KanumilliN,ButlerJ.Predictorsofheartfailuredevelopmentintype2diabetes:Apracticalapproach.CurrOpinCardiol2019;34:578‚Äì583.https://doi.org/10.1097/HCO.0000000000000647¬©2023EuropeanSocietyofCardiology.

---

### Chunk 26/30
**Article:** Relationship of TAPSE Normalized by Right Ventricular Area With Pulmonary Compliance, Exercise Capacity, and Clinical Outcomes (2024)
**Journal:** Circulation: Heart Failure
**Section:** abstract | **Similarity:** 0.535

Study introducing normalized TAPSE values (TAPSE/RVA-D and TAPSE/RVA-S) for improved prognostic assessment. TAPSE/RVA-D <1.1 and TAPSE/RVA-S <1.5 predicted adverse cardiovascular outcomes, providing better discrimination than traditional TAPSE alone. Demonstrates relationship between normalized TAPSE and pulmonary compliance and exercise capacity in heart failure patients.

---

### Chunk 27/30
**Article:** Echocardiographic Reference Ranges of Global Longitudinal Strain for All Cardiac Chambers Using Guideline-Directed Dedicated Views (2024)
**Journal:** JACC: Cardiovascular Imaging
**Section:** abstract | **Similarity:** 0.535

Estudo estabeleceu valores de refer√™ncia para strain longitudinal global de todas c√¢maras card√≠acas usando imagens obtidas conforme recomenda√ß√µes da ASE/EACVI. Incluiu 1.329 participantes saud√°veis do estudo HUNT4Echo. Valores de refer√™ncia para GLS do ventr√≠culo esquerdo: -24% a -16%. Todos os strains associaram-se com idade, e GLS ventricular esquerdo associou-se com sexo. World Alliance Societies of Echocardiography prop√¥s valores normais: -17% a -24% para homens e -18% a -26% para mulheres. Define-se GLS normal como ‚â§-18% e anormal como ‚â•-16%.

---

### Chunk 28/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.534

sensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwithamorethantwo-foldhigherriskofheartfailurehospitalizationand50%higherriskofmortalityascomparedwithanNT-proBNPof400‚Äì2000pg/ml.47Wesug-gestthat,irrespectiveofageandsex,patientswithanNT-proBNP
>2000pg/mlshouldbeprioritizedforechocardiographyandclini-calevaluationwithin2weeksofdiagnosis(Figure2).NT-proBNPinasymptomaticpatientswithriskfactors:heart
stressVariousriskfactors,suchashypertension,atheroscleroticcardio-vasculardisease,diabetes,obesity,andothers,contributetoanincreasedsusceptibilitytothedevelopmentofheartfailure.Intheabsenceofsymptomsofheartfailure,patientswithriskfactorsmay
exhibiteitherhearthealthorheartstress.Hearthealthrefersto
individualswhohaveastructurallynormalheartandnormalplasma
concentrationsofNPsandtroponins.¬©2023EuropeanSocietyofCardiology.

---

### Chunk 29/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.534

olisA,McMurrayJ,PonikowskiP,RosenhekR,Ruschitzka
F,SavelievaI,SharmaS,SuwalskiP,
TamargoJL,TaylorCJ,vanGelderIC,VoorsAA,WindeckerS,ZamoranoJL,ZeppenfeldK.2016ESCguidelinesfor
themanagementofatrialbrillationde-velopedincollaborationwithEACTS.EurHeartJ.2016;37:2893‚Äì2962.2.YancyCW,JessupM,BozkurtB,ButlerJ,CaseyDEJr,DraznerMH,Fonarow
GC,GeraciSA,HorwichT,JanuzziJL,
JohnsonMR,KasperEK,LevyWC,MasoudiFA,McBrideP,McMurrayJ,MitchellJE,PetersonPN,RiegelB,Sam
F,StevensonLW,TangWH,TsaiEJ,
6A.M.Marraetal.ESCHeartFailure(2022)DOI:10.1002/ehf2.14117
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

WilkoffBL,AmericanCollegeofCardiol-ogyFoundation,AmericanHeartAssoci-ationTaskForceonPracticeGuidelines.2013ACCF/AHAguidelinefortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147‚Äìe239.3.BealeAL,MeyerP,MarwickTH,

---

### Chunk 30/30
**Article:** Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study (2020)
**Journal:** European Journal of Preventive Cardiology
**Section:** results | **Similarity:** 0.533

o Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. Am J Cardiol 2016;118:647‚Äì55. [PubMed: 27392507] 
16. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687‚Äì702. [PubMed: 2646917] 
17. Meeusen JW, Lueke AJ, Jaffe AS, Saenger AK. Validation of a proposed novel equation for estimating LDL cholesterol. Clin Chem 2014;60:1519‚Äì23. [PubMed: 25336719] 
18. Lee J, Jang S, Son H. Validation of the Martin Method for Estimating Low-Density Lipoprotein Cholesterol Levels in Korean Adults: Findings from the Korea National Health and Nutrition Examination Survey, 2009‚Äì2011. PLoS One 2016;11:e0148147. [PubMed: 26824910] 
Quispe et al.Page 10
Eur J Prev Cardiol. Author manuscript; available in PMC 2021 October 01.
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript

19.

---

